New Candidates for Biomarkers and Drug Targets of Ischemic Stroke-A First Dynamic LC-MS Human Serum Proteomic Study

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 Jan 21

PMID 35054033

Authors

Aleksandra Turek-Jakubowska

Janusz Debski

Maciej Jakubowski

Ewa Szahidewicz-Krupska

Jakub Gawrys

Karolina Gawrys

Agnieszka Janus

Malgorzata Trocha

Adrian Doroszko

Affiliations

Soon will be listed here.

Abstract

(1) Background: The aim of this dynamic-LC/MS-human-serum-proteomic-study was to identify potential proteins-candidates for biomarkers of acute ischemic stroke, their changes during acute phase of stroke and to define potential novel drug-targets. (2) Methods: A total of 32 patients (29-80 years) with acute ischemic stroke were enrolled to the study. The control group constituted 29 demographically-matched volunteers. Subjects with stroke presented clinical symptoms lasting no longer than 24 h, confirmed by neurological-examination and/or new cerebral ischemia visualized in the CT scans (computed tomography). The analysis of plasma proteome was performed using LC-MS (liquid chromatography-mass spectrometry). (3) Results: Ten proteins with significantly different serum concentrations between groups volunteers were: complement-factor-B, apolipoprotein-A-I, fibronectin, alpha-2-HS-glycoprotein, alpha-1B-glycoprotein, heat-shock-cognate-71kDa protein/heat-shock-related-70kDa-protein-2, thymidine phosphorylase-2, cytoplasmic-tryptophan-tRNA-ligase, ficolin-2, beta-Ala-His-dipeptidase. (4) Conclusions: This is the first dynamic LC-MS study performed on a clinical model which differentiates serum proteome of patients in acute phase of ischemic stroke in time series and compares to control group. Listed proteins should be considered as risk factors, markers of ischemic stroke or potential therapeutic targets. Further clinical validation might define their exact role in differential diagnostics, monitoring the course of the ischemic stroke or specifying them as novel drug targets.

Citing Articles

Body fluid multiomics in 3PM-guided ischemic stroke management: health risk assessment, targeted protection against health-to-disease transition, and cost-effective personalized approach are envisaged.

Chen R, Wang X, Li N, Golubnitschaja O, Zhan X EPMA J. 2024; 15(3):415-452.

PMID: 39239108 PMC: 11371995. DOI: 10.1007/s13167-024-00376-2.

Promising therapeutic targets for ischemic stroke identified from plasma and cerebrospinal fluid proteomes: a multicenter Mendelian randomization study.

Zou X, Wang L, Wang S, Zhang Y, Ma J, Chen L Int J Surg. 2023; 110(2):766-776.

PMID: 38016292 PMC: 10871597. DOI: 10.1097/JS9.0000000000000922.

Proteomic advance of ischemic stroke: preclinical, clinical, and intervention.

Zhao T, Zeng J, Zhang R, Pu L, Wang H, Pan L Metab Brain Dis. 2023; 38(8):2521-2546.

PMID: 37440002 DOI: 10.1007/s11011-023-01262-y.

Association of low ficolin-2 concentration in cord serum with respiratory distress syndrome in preterm newborns.

Gajek G, Swierzko A, Jarych D, Mikulski D, Kobiela P, Chojnacka K Front Immunol. 2023; 14:1107063.

PMID: 36733481 PMC: 9886859. DOI: 10.3389/fimmu.2023.1107063.

References

Hollander Z, Dai D, Putko B, Yogasundaram H, Wilson-McManus J, Thompson R . Gender-specific plasma proteomic biomarkers in patients with Anderson-Fabry disease. Eur J Heart Fail. 2015; 17(3):291-300. DOI: 10.1002/ejhf.230. View

Miyadera K, Sumizawa T, Haraguchi M, Yoshida H, Konstanty W, Yamada Y . Role of thymidine phosphorylase activity in the angiogenic effect of platelet derived endothelial cell growth factor/thymidine phosphorylase. Cancer Res. 1995; 55(8):1687-90. View

Arumugam T, Woodruff T, Lathia J, Selvaraj P, Mattson M, Taylor S . Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience. 2008; 158(3):1074-89. PMC: 2639633. DOI: 10.1016/j.neuroscience.2008.07.015. View

Kim B, Winstein C . Can Neurological Biomarkers of Brain Impairment Be Used to Predict Poststroke Motor Recovery? A Systematic Review. Neurorehabil Neural Repair. 2016; 31(1):3-24. DOI: 10.1177/1545968316662708. View

Orsini F, De Blasio D, Zangari R, Zanier E, De Simoni M . Versatility of the complement system in neuroinflammation, neurodegeneration and brain homeostasis. Front Cell Neurosci. 2014; 8:380. PMC: 4224073. DOI: 10.3389/fncel.2014.00380. View

Fontes J, Yamamoto J, Larson M, Wang N, Dallmeier D, Rienstra M . Clinical correlates of change in inflammatory biomarkers: The Framingham Heart Study. Atherosclerosis. 2013; 228(1):217-23. PMC: 3650714. DOI: 10.1016/j.atherosclerosis.2013.01.019. View

Ikeda R, Furukawa T, Kitazono M, Ishitsuka K, Okumura H, Tani A . Molecular basis for the inhibition of hypoxia-induced apoptosis by 2-deoxy-D-ribose. Biochem Biophys Res Commun. 2002; 291(4):806-12. DOI: 10.1006/bbrc.2002.6432. View

Reina S, Llabre M, Allison M, Wilkins J, Mendez A, Arnan M . HDL cholesterol and stroke risk: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis. 2015; 243(1):314-9. PMC: 4609625. DOI: 10.1016/j.atherosclerosis.2015.09.031. View

Adebamowo S, Spiegelman D, Flint A, Willett W, Rexrode K . Intakes of magnesium, potassium, and calcium and the risk of stroke among men. Int J Stroke. 2015; 10(7):1093-100. DOI: 10.1111/ijs.12516. View

10.

Gariballa S, Robinson T, Fotherby M . Hypokalemia and potassium excretion in stroke patients. J Am Geriatr Soc. 1997; 45(12):1454-58. DOI: 10.1111/j.1532-5415.1997.tb03195.x. View

11.

Dassan P, Keir G, Brown M . Criteria for a clinically informative serum biomarker in acute ischaemic stroke: a review of S100B. Cerebrovasc Dis. 2009; 27(3):295-302. DOI: 10.1159/000199468. View

12.

Huang P, Lo L, Chen Y, Lin R, Shiea J, Liu C . Serum free hemoglobin as a novel potential biomarker for acute ischemic stroke. J Neurol. 2009; 256(4):625-31. DOI: 10.1007/s00415-009-0133-x. View

13.

Bhatia M, Howard S, Clark T, Neale R, Qizilbash N, Murphy M . Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack. Cerebrovasc Dis. 2006; 21(5-6):323-8. DOI: 10.1159/000091537. View

14.

Milton M, Smith P . It's All about Timing: The Involvement of Kir4.1 Channel Regulation in Acute Ischemic Stroke Pathology. Front Cell Neurosci. 2018; 12:36. PMC: 5820340. DOI: 10.3389/fncel.2018.00036. View

15.

Alawieh A, Elvington A, Zhu H, Yu J, Kindy M, Atkinson C . Modulation of post-stroke degenerative and regenerative processes and subacute protection by site-targeted inhibition of the alternative pathway of complement. J Neuroinflammation. 2015; 12:247. PMC: 4696299. DOI: 10.1186/s12974-015-0464-8. View

16.

Palmer B, Clegg D . Achieving the Benefits of a High-Potassium, Paleolithic Diet, Without the Toxicity. Mayo Clin Proc. 2016; 91(4):496-508. DOI: 10.1016/j.mayocp.2016.01.012. View

17.

Vasan R . Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation. 2006; 113(19):2335-62. DOI: 10.1161/CIRCULATIONAHA.104.482570. View

18.

Habryka A, Gogler-Piglowska A, Sojka D, Kryj M, Krawczyk Z, Scieglinska D . Cell type-dependent modulation of the gene encoding heat shock protein HSPA2 by hypoxia-inducible factor HIF-1: Down-regulation in keratinocytes and up-regulation in HeLa cells. Biochim Biophys Acta. 2015; 1849(9):1155-69. DOI: 10.1016/j.bbagrm.2015.07.004. View

19.

Chamorro A, Vila N, Ascaso C, Saiz A, Montalvo J, Alonso P . Early prediction of stroke severity. Role of the erythrocyte sedimentation rate. Stroke. 1995; 26(4):573-6. DOI: 10.1161/01.str.26.4.573. View

20.

Lindenstrom E, Boysen G, Nyboe J . Influence of total cholesterol, high density lipoprotein cholesterol, and triglycerides on risk of cerebrovascular disease: the Copenhagen City Heart Study. BMJ. 1994; 309(6946):11-5. PMC: 2542648. DOI: 10.1136/bmj.309.6946.11. View